LY2127399: Phase III started

Eli Lilly disclosed in its 4Q10 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial

Read the full 175 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE